Therapeutic Solutions International Issues
"NOT US" Notice to Shareholders
OCEANSIDE, CA --
June 14, 2020 --
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) issues the following
cautionary notice to the shareholders and public at
large.
This morning it was
discovered that a person or persons had published "Fake News"
concerning the Company's FDA Registered upcoming Clinical Trial of
QuadraMune™. The fake news below
was published on Google Sites at this address that has been since
shut down. https://sites.google.com/view/pennytradeinsider/menu/healthcare/newsroom
Therapeutic Solutions
International, Inc. boldly states that what is contained below is
absolutely false even if it contains an accurate quote from
Officers of the Company. We have publicly
posted on our social media as well that is categorically
false. Our lawyers are now
in charge of this matter and any questions concerning this should
be addressed in writing to Mr. Hugh
D. Kelso III, Esq, Managing Attorney,
8799
Balboa Avenue, Suite 155 San Diego, CA 92123.
UC San Diego
Health Conducts COVID-19
Trial
Therapeutic
Solutions International Initiates 500 Volunteer Prevention Clinical
Trial Using QuadraMune™
San
Diego– UC San Diego Medical Center will lead the first large-scale
study in the United States of the effectiveness of QuadraMune™
in
preventing COVID-19 in healthcare workers and first responders who
volunteer to participate. The study of QuadraMune has begun in
earnest after a collaborative effort by Dr. James Veltmeyer, Therapeutic
Solutions International and several major California medical
centers.
Therapeutic
Solutions International is focused on immune modulation for the
treatment of several specific diseases using their proprietary drug
formulation QuadraMune™
"This
is going to be the first major, definitive study in healthcare
workers and first responders of QuadraMune as a preventative
medication," said the study's organizer, UC San Diego Health
Centers Dr. Ehtisham
Mahmud , a
world-renowned interventional cardiologist and researcher who has
pioneered multiple treatments for heart disease. "There has been a
lot of talk about this drug, but only a small, non-blinded study
so far
. We are
going to change that in San Diego and produce a scientific answer
to the question: Does it work?"
Dr.
James Veltmeyer
, San
Diego's leading physician and Chief Medical Officer of Therapeutic
Solutions International will oversee the study with Dr.
Ehtisham
Mahmud.
"We at
Therapeutic Solutions International are pleased to apply our work
in the area of inflammation and immune stimulation, to attempt to
add another arrow in our quiver against this invisible enemy," said
Timothy Dixon, President, and CEO of Therapeutic Solutions
International. "In some ways, Coronavirus is like cancer…you want
to increase activation of innate immunity and suppress inflammatory
reactions simultaneously. We have been doing this research
successfully using NanoStilbene™ in cancer, and now we are
transposing our findings into the field of virology with
QuadraMune.
"We
are glad to see UC San
Diego's
lead on this volunteer study that could help protect medical
workers and first responders across the country " remarked CEO
Christopher Kane of UC San Diego Health Physician Group.
Both
health care workers and first responders will also be enrolled at
UCLA Medical Center and Cedars-Sinai Medical Center. Any hospital
healthcare worker within the Metro San Diego area will be able to
volunteer to participate, including those from the San Diego COVID
Consortium, a recently announced healthcare collaboration on
COVID-19 research that includes Stanford Health Care and University
of California, Davis Medical Center. Dr. Ehtisham
Mahmud
recently organized the group to efficiently coordinate and
disseminate information about large-scale studies of COVID-19
treatments and bring those measures to healthcare workers
sooner.
The
study, titled QuadraMune(TM) for Prevention
of COVID-19 is a
500+ subject look at whether the drug prevents front-line workers
from contracting the virus. Once they provide a blood sample, the
study subjects will receive vials with unidentified, specific pills
to take over the next 5 months. A once-a-week dose of QuadraMune
and a once-a-day dose of a placebo pill that looks like the
medication,
but does
not contain any medication or other active ingredients will be
administered. The study medication was specially procured for this
study and will not impact the supply of medication for people who
already take the medication for other conditions.
Participants
will not know what group they are in. They will then be contacted
weekly and in person at week 4 and week 8 of the study to see if
they are exhibiting any symptoms of COVID-19, including dry cough,
fever or breathing issues, as well as any medication side effects.
At eight weeks, they will be checked again for symptoms, medication
side effects, and have blood drawn. Results will be compared among
the three groups to see if the medication had any
effect.
"Given
our broad clinical trials and translational research
infrastructure, we are grateful to bring this type of large-scale
effort to the COVID-19 battle," said Dr. Veltmeyer "We see the
heroics of the frontline responders in healthcare, public safety
and service. and we will do anything we can to help them stay
safe."
Therapeutic
Solutions International will provide the drug directly to
UC San Diego Health
and
UCLA Medical Center physicians to distribute.
Recruiting
has recently begun, more information can be found at
https://clinicaltrials.gov/ and
www.therapeuticsolutionsint.com.
The
CDC describes QuadraMune™, as a relatively well-tolerated medicine.
The most common adverse reactions reported are minor stomach pain,
and nausea.
If the
study finds the drug effective as a preventative medication for
COVID-19, it is possible that the study could expand to include
QuadraMune in other COVID-19 treatment options..
The
drug is an off-label treatment for only health care and frontline
COVID-19 responders who meet specific criteria as outlined by the
hospital system's Division of Infectious Diseases. As required by
the state of California's Department of Licensing and Regulatory
Affairs, the physicians are documenting the prescribed use in the
patient's electronic medical record.
UC San Diego Medical
Center
as one of the region's major academic medical centers with more
than $100 million in annual research funding, is already involved
in numerous COVID-19 trials with partners around the
world.
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is at
www.therapeuticsolutionsint.com
and our
e-commerce is at www.youcanordernow.com and for additional
info on QuadraMune™
visit www.areyoucovidmune.com/covidmune/.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
Therapeutic Solutions
International, Inc.
ir@tsoimail.com
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2023 to Mar 2024